Could a new PET scan help match pancreatic cancer patients to the right therapy?
NCT ID NCT03851237
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1 trial tested a new radioactive imaging agent called 64Cu-DOTA-ECL1i to see if it can detect a protein called CCR2 in pancreatic tumors using PET scans. The study involved 69 adults with pancreatic ductal adenocarcinoma at various stages. The goal was to see if the scan could predict how well patients would respond to standard chemotherapy or a CCR2-targeted therapy, potentially helping doctors choose the best treatment for each patient.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- 64Cu-DOTA-ECL1i (a radioactive imaging agent)
- What this could lead to
- If successful, this imaging test could help doctors identify which pancreatic cancer patients are likely to respond to CCR2-targeted therapy, avoiding ineffective treatments.
- What could go wrong
- This is an early phase 1 study with only 69 participants, so the imaging agent may not reliably predict treatment response in larger, more diverse groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
69 people
The number who actually took part.
- Started
-
Jan 2019
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adult patients 18 years of age or older with: * newly diagnosed early-staged localized pancreatic ductal adenocarcinoma (PDAC) scheduled to undergo Whipple procedure (cohort 1a) or down-staged after neoadjuvant chemotherapy now eligible to undergo resection OR * borderline resectable, locally advanced, metastatic, or recurrent PDAC (cohort 1b) scheduled to undergo chemotherapy OR * borderline resectable, locally advanced PDAC (cohort 2) who is eligible and / or signed consent to undergo CCR2-targeted therapy example:\[(phase 1/2 clinical trial combining an oral CCR2/5i (BMS-813160) with chemotherapy (gemcitabine plus nab-paclitaxel) and anti-PD-1 (nivolumab), PI, Dr. Kian Lim) HRPO #201806007 - closed to accrual March 2022\] AND * at least one measurable \[defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm with CT scan or MRI\] A cohort 1B subject who has been previously treated for PDAC with a diagnosis of recurrence and a lesion size of 1.5 cm or greater will be allowed to enroll before institution of therapy or within 20 days after starting a 2nd line or later (new therapy) for recurrent disease. * Able to give informed consent * Not currently pregnant or nursing: Subject must be surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), post-menopausal (cessation of menses for more than 1 year), non-lactating, or of childbearing potential for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of 64Cu-DOTA-ECL1i) is negative Exclusion Criteria: * Patients with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of the other cancer present within the last 5 years * Unable to tolerate up to 90 min of PET/CT imaging per imaging session.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pancreatic ductal adenocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can digital questionnaires improve life during pancreatic cancer therapy?
- Can a phone app help pancreatic cancer patients eat better during treatment?
- Can a Dietitian's plan help older pancreatic cancer patients feel better?
- Can a vaccine stop GI cancers from returning?
- Triple therapy aims to stall pancreatic cancer
- Can removing more tissue around pancreatic tumors stop cancer from coming back?